VivoSeq
Oncology

Rhabdomyosarcoma

66

Pipeline Programs↗

16

Active Trials↗

25

Companies Involved↗

Rhabdomyosarcoma is a moderately active landscape with 66 programs across 25 companies. The most active players are Horizon Therapeutics Ireland DAC, Imclone, Mirati Therapeutics Inc.. 1 therapy is approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

19/100

Mech. Concentration

14/100

Completion Rate

83/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Horizon Therapeutics Ireland DAC

1 program

Phase 1I

Imclone

1 program

Phase 1M

Mirati Therapeutics Inc.

1 program

Phase 1Pfizer logo

Pfizer

3 programs

Phase 2Bayer logo

Bayer

2 programs

Phase 2Amgen logo

Amgen

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

53 of 67 classified programs — the dominant modality here.

21%ALL OTHERSProtein / enzyme69%Monoclonal antibody57%Cell therapy11%Vaccine11%Radiopharmaceutical11%

Small molecule leads; the ring shows all 67 classified programs, each share of the total. Modality classified for 100% of 69 pipeline programs.

Analysis

Trial Status

44

clinical trials

Completed19 · 43%
Recruiting6 · 14%
Active, not recruiting6 · 14%
Unknown status5 · 11%
Not yet recruiting4 · 9%
Withdrawn2 · 5%
Other2 · 5%

Clinical Trials

Trial Activity

44 trials

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06816771·38 enrolled
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06865664·50 enrolled
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06023641·135 enrolled
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Recruiting·Children's Oncology Group·Phase 3·NCT05304585·205 enrolled
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
Recruiting·SSun Yat-sen University·Phase 2·NCT05457829·88 enrolled
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Active, not recruiting·Children's Oncology Group·Phase 3·NCT04994132·118 enrolled
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04299113·38 enrolled
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02567435·325 enrolled
Evolutionary Therapy for Rhabdomyosarcoma
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04388839·12 enrolled
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00077285·65 enrolled
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled
A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
Not yet recruiting·FFudan University·Phase 2·NCT07355855·106 enrolled
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Not yet recruiting·Children's Oncology Group·Phase 3·NCT07466316·342 enrolled
Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
Not yet recruiting·—·Phase 1·NCT06932861·5 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)